

Index

Page numbers followed by “f” indicate figures; those followed by “t” indicate tables.

- AICNow home glucose monitoring (HGM) device, 34f
- A1C (glycosylated hemoglobin)
 - blood glucose
 - meters and, 302
 - control and, 324
 - compared with, 324t
 - bolus onboard and, 163
 - carbohydrate absorption inhibitors and, 111t
 - in case studies, 124-126, 147-150, 180, 197-198, 208-209, 249, 282, 354
 - clinical trial results, 29, 30f, 324
 - computerized data on, 302
 - continuous glucose monitoring (CGM) impact on, 186
 - dentist, information for, 281
 - as glucose-control factor, 40, 207
 - vs glucose readings, 35f, 201-203
 - high
 - consequences of, 31
 - with smart pump, 156t
 - importance of, 52, 56f
 - improvement of, 135, 138, 161, 305
 - insulin impact on, 138, 138t
 - insulin pump vs injection impact on, 159
 - medications affecting, 110, 148, 209
 - overview of, 33-35, 34f
 - poorly controlled, 135
 - postmeal hyperglycemia and, 110
 - range, normal, 243, 305, 357
 - score goals, 33t, 243, 305, 357
 - test
 - availability of, 14, 36, 52, 61
 - cost of, 327
 - home glucose monitors (HGMs) and, 14
 - values, increasing, 260
- Abbott Diabetes Care, Inc., 374-375, 379t-380t
- Abbott Laboratories, 381t
- Acanthosis nigricans, 283, 283t, 286, 286f, 290, 340
- Acarbose (Precose). *See* Precose (acarbose)
- Accu-Chek Spirit (Disetronic) (insulin pump), 166f
- Accupril (quinapril), 219t, 246t
- Accuretic, 219t
- ACE (angiotensin-converting enzyme) inhibitors, 123-125, 218, 219t, 220-221, 239, 244t, 245-247, 246t, 250
 - in calcium channel blocker combinations, 219t
 - in diuretic combinations, 219t
- Accon (perindopril), 219t, 246t
- Acetohexamide (Dymelor). *See* Dymelor (acetohexamide)
- Aciphex (rabeprazole), 266, 268
- Acomplia (rimonabant), 215
- Act Now study, 349
- Actoplus Met (pioglitazone/metformin), 115t
- Actos (pioglitazone), 94, 111-113, 112t, 118, 124-126, 148, 272, 346, 349
- Adalat (nifedipine), 219t
- ADOPT (A Diabetes Outcome Progression Trial), 105-106, 106f
- Adrenalin, 185, 193, 200, 293
- Advantage Health Services, 372
- Advicor (lovastatin/niacin ER), 224t
- Agent Orange, 320
- Albumin
 - ACE inhibitors and, 246
 - ARB and, 246
 - blood pressure control and, 245t

Albumin (*continued*)
 creatinine ratio, to, 240-241
 in diabetic kidney disease, presence of, 239-240
 excretion rates, 240t
 in urine, 240, 242, 244, 274
 life insurance application denied because of, 240
 reducing, 245
 timed collection, tests for, 240
 long-acting basal insulin analogue, bound to, 133
 Alcohol, 76-77, 82, 181, 203-204
 Aldactazide, 219t
 Aldomet (methyldopa), 219t
 Aldoril, 219t
 Aliskiren (Tekturna). *See* Tekturna (aliskiren)
 Alpha
 -blockers, 219t, 220
 cells, 200
 lipoic acid, 233
 Altace (ramipril), 219t, 246t, 346t
 Altacor (lovastatin), 224t, 248t
 Alzheimer's disease, 60f
 Amaryl (glimepiride), 94, 105t, 193, 273
 American Association of Diabetes Educators (AADE), 368
 American Diabetes Association, 25, 98, 216, 243-244, 251, 327, 350, 357, 367
 American Dietetic Association, 368
 Americans With Disabilities Act, 319, 334, 369
 Amitriptyline, 232
 Am lactin, 290
 Amlodipine/atorvastatin (Caduet). *See* Caduet (amlodipine/atorvastatin)
 Amlodipine (Norvasc). *See* Norvasc (amlodipine)
 Ammonium lactate, 286
 Amputations
 cause of, 27, 229, 340-341
 expenditures on, 345
 fear of, 48, 319
 preventing, 51, 236
 quality of life, impact on, 87
 vascular disease role in, 233
 Amylin, 38, 135-136
 Anemia, 270
 Anger, 46, 46t
 Animas
 Corp., 166f, 375
 insulin pump, 166f, 190
 Ankle edema, 113, 113t
 Antara (fenofibrate), 224t, 225
 Antibiotics, 290
 Antidepressant medications, 51, 232-233, 269
 Antiendomysial antibodies, 270
 Antifungal solutions and creams, 284-285
 Antigliadin antibodies, 270
 Antihistamines, 290
 Anti-inflammatory medications, 262, 264
 Antioxidants, 222, 226, 233, 243, 244t, 248-250
 Antiseizure medications, 232
 Antispasmodic medicines, 271
 Antitissue transglutaminase antibodies, 270
 Antiyeast solutions and creams, 285
 Apidra (glulisine), 59f, 64, 100, 131t, 132f, 134, 136, 143t, 144f, 145t, 146-147, 163, 176-178, 180, 182-183, 187, 249
 Appetite
 changes in, 48
 loss of, 273, 274
 satiety and, 116f, 117, 136, 138
 Aquaphor, 290
 ARBs (angiotensin receptor blockers), 218, 219t, 220-221, 239, 244t, 246-247, 247t, 250
 in diuretic combinations, 219t

Arthritis, 96, 261f, 263
 Aspart (Novolog). *See* Novolog (aspart)
 Aspirin, 59f, 226-228, 287, 351
 Atacand (candesartan), 219t, 247t
 Atacand HCT, 219t
 Atenolol (Tenormin). *See* Tenormin (atenolol)
 Atherosclerosis
 family history of, 214
 fatal, 227
 impact of, 213t, 233-234
 overview of, 211
 preventing, 218, 226-228
 risk factors for, 222, 227
 Athletes
 case studies of, 190-191
 organizations for, 146, 368
 personal accounts of, 319-320
 publications for, 373
 self-care for, 85, 101, 102
 Athlete's foot (tinea pedis), 284f
 Atorvastatin (Lipitor). *See* Lipitor (atorvastatin)
 Atorvastatin/amlodipine (Caduet). *See* Caduet (amlodipine/atorvastatin)
 Atropine/diphenoxylate (Lomotil). *See* Lomotil (diphenoxylate/atropine)
 Autoimmune condition, 20, 269
 Autoimmune diabetes, 21
 Autonomic neuropathy, 97, 99t, 153
 Avalide, 219t
 Avandamet (rosiglitazone/metformin), 115t
 Avandaryl (rosiglitazone/glimepiride), 115t
 Avandia (rosiglitazone), 94, 106f, 111-113, 112t, 118, 124-126, 193, 257, 272, 346, 346t, 349-350, 354
 Avapro (irbesartan), 219t, 247t
 Avastin (bevacizumab), 255, 256f
 Axid (nizatidine), 268

 Bacterial overgrowth syndrome, 268-269
 Bad breath (halitosis), 278, 278t
 Basal
 /bolus balance, 164
 /bolus or basal/prandial insulin regimen, 147-148, 150, 151t
 insulin, 131t, 133-135, 146, 148, 151t, 153-154, 154t, 157, 176, 181, 194-195
 doses, 303
 profiles, 164
 rates, 154-155, 157, 160, 166, 184, 186
 Bayer Diagnostic Division, 34
 Bayer HealthCare, LLC, 378t
 Bayer HealthCare Diabetes Care, 374
 Behavior, changing, 71, 72-73
 Behavioral Diabetes Institute, 369
 Belladonna/phenobarbital (Donnatal). *See* Donnatal (belladonna/phenobarbital)
 Benazepril (Lotensin). *See* Lotensin (benazepril)
 Benicar HCT, 219t
 Benicar (olmesartan), 219t, 247t
 Bentyl (dicyclomine), 271
 Berkson, Richard, 15
 Beta
 -adrenergic blocker/diuretic combinations, 219t
 -blockers, 219t, 221
 cells, 21, 38, 157, 199-200, 208
 Betaxolol (Kerlone). *See* Kerlone (betaxolol)
 Bevacizumab (Avastin). *See* Avastin (bevacizumab)
 Biguanides, 104, 107-110, 109t
 Bile acid sequestrants, 224t, 225
 Bisacodyl (Dulcolax). *See* Dulcolax (bisacodyl)
 Bisoprolol (Zebeta). *See* Zebeta (bisoprolol)
 Bisphosphonate therapy, 263

Blindness

- causes of, 27, 51, 97-98, 251-253
- fear of, 48, 319
- preventing, 19, 251-255, 252t, 258
- quality of life, impact on, 87
- as workplace challenge, 315

Bloating, 270, 274

Blood flow problems, 90t, 229, 233-234, 236

Blood glucose meters. *See* Glucose: meters

Blood pressure

- controlling, 51, 77, 82, 112, 214-221, 219t, 226, 239, 243-245, 244t-245t, 250, 357
- diastolic, 244, 245t
- exercise impact on, 85
- goals and values, 216, 216t, 218
- high. *See* High blood pressure
- medications for, 216t, 217-221, 219t, 228, 250, 357-358
- monitoring, 45, 52, 60, 215-216, 242, 243f, 357
- normal (defined), 243-244
- systolic, 244, 245t

Blood transfusions, 337

Blood vessels, glucose levels, impact on, 21, 27

Blumer, Ian, 60-63

Blurry vision, 32, 311

BMI (body mass index), 69, 70t, 167-168

BOBs (boluses onboard), 154, 156, 158, 160-163, 165, 167

Body mass index (BMI), 69, 70t, 167-168

Boluses, 153-157, 160, 163-164, 166-167

onboard (BOB), 154, 156, 158, 160-163, 165, 167

Bolus insulin doses, 303

Bone fractures, 230-231

Botox injections, 267

Brain, low glucose concentration impact on, 201-202, 205

Breastfeeding, medications to avoid during, 103

Bristol-Myers Squibb, 371

Brittle diabetes (defined), 20

Bumetanide (Bumex). *See* Bumex (bumetanide)

Bumex (bumetanide), 110

Business, owning, 315-319

Byetta (exenatide), 23, 95, 115, 117-119, 118t, 119t, 121, 124-126, 124f, 161, 209, 215, 328

Byetta LAR (long-acting release), 119

Bypass surgery, 234

Caduet (amlodipine/atorvastatin), 219t, 224t

Calan SR (verapamil), 219t

Calcium channel blockers, 219t, 220-221

ACE inhibitor, in combination with, 219t

Calibration of CGM devices, 175

Calorie King (website), 369

Calories

- limiting, 84
- protein foods as source of, 77
- requirements, determining, 68-69

Cancer

family history of, 60f

risk vs exercise, 85

Candesartan (Atacand). *See* Atacand (candesartan)

Candidiasis (fungal infection), 266, 277-278, 285f

Capoten (captopril), 219t, 246t

Capsulitis, adhesive (frozen shoulder), 59t, 92, 262

Capsaicin cream, 233

Captopril (Capoten). *See* Capoten (captopril)

Captozide, 219t

Carbamazepine (Tegretol). *See* Tegretol (carbamazepine)

Carbohydrate

- absorption inhibitors, 104, 110-111, 110t, 111t, 346, 350
- absorption of, 97, 274

Carbohydrate (*continued*)
 allowance, daily of, 73, 73t
 boluses, 154t, 155-156, 161, 163
 controlling, 74-77
 counting, 141-142, 147, 150-151, 155, 161, 187, 195, 303, 309
 exercise and, 100
 factor, 155, 157-158, 160-161
 foods containing, 69, 71, 71t-72t, 79, 82-83
 glucose, conversion into, 83
 hypoglycemia, treating with, 93
 intake, high of, 187-188
 monitoring, 45
 replenishment through exercise, 87
 sugar, relationship with, 83

Cardene (nicardipine), 219t

Cardiac stress test, 227

Cardiovascular
 advantage, gender-related, 212
 disease
 and exercise, 89, 98
 preventing, 342
 and sleep apnea, 291-292, 297, 299-300

Cardizem CDE (diltiazem HCl), 59f

Cardizem (diltiazem), 219t

Cardura (doxazosin), 219t

Career
 changes, 317
 outlook for diabetes patients, 318

Carmol-40, 284

Carpal tunnel release surgery, 262

Carpal tunnel syndrome (CTS), 92, 261-262

Cartia XT (diltiazem), 219t

Carvedilol (Coreg). *See* Coreg (carvedilol)

Catapres/Catapres-TTS (clonidine), 219t, 220

Causes of diabetes
 theories on, 313
 type 1, 20, 21t, 23
 type 2, 21t, 23

CCS Medical (online stores), 372

Celiac disease, 269-270

Celiac sprue, 266t

Center for Disease Control International Traveler Hotline, 371

Centers for Disease Control (CDC), 368

Centrally acting agents, 219t, 220

Central nervous system, 97

Cetaphil, 290

Charcot's joint (osteoarthropathy), 230-231, 231f, 263

Cheiroarthropathy (limited joint mobility), 59f, 259-260, 260f, 264

Chemstrips (blood glucose test strips), 323, 325-326, 328

Children with diabetes
 legal rights of, 335-336, 336t, 370
 online resources for, 368-369
 television coverage of, 361
 type 2 diabetes, 339-343

Chlorothiazide (Diuril). *See* Diuril (chlorothiazide)

Chlorpropamide (Diabinese). *See* Diabinese (chlorpropamide)

Choking and gasping during sleep, 293-294, 293t

Cholesterol
 abnormal levels
 as circulatory problem factor, 234, 236
 diabetes as risk factor for, 221
 as diabetes risk factor, 26, 348t, 351, 354
 vs exercise, 90t
 fat limitations in event of, 179
 as heart disease risk factor, 213-215
 and liver disorders, 272

Cholesterol, abnormal levels (*continued*)

- medication for, 194
- as oral medication selection factor, 120t, 124-125
- as silent killer, 227
- in type 2 diabetes, 20, 22, 222t
- controlling, 51, 77, 81-82, 112, 125, 215, 219t, 220-223, 222t, 227, 243, 244t, 248, 250, 357
- fat effect on, 68, 77
- medications for, 219t, 223-226, 224t, 228, 248t, 358
- monitoring, 45, 52, 56f, 63, 358. *See also* Lipid: panel
- types of, 221

Cholesterol absorption inhibitors, 224t

Cholestyramine (Questran). *See* Questran (cholestyramine)

Chronic

- health problems, reducing through exercise, 85-86
- obstructive pulmonary disease (COPD), 135
- pain, 87
- ulcers (skin), 287

Cimetidine (Tagamet). *See* Tagamet (cimetidine)

Circulatory problems, 90t, 229, 233-234, 236

Cirrhosis, 272

Cisapride (Propulsid). *See* Propulsid (cisapride)

Citrucel, 270-271

Clinical centers, 370

Clinical trials

- on diabetes prevention, 346t, 347-350, 352, 353
- on eye medications, 255, 257
- on glucose control, 323-324. *See also* Diabetes Control and Complications Trial (DCCT)
- on protein intake, 247
- on sulfonylureas, 105-106, 106f
- on Symlin, 136, 137f, 138-139
- volunteering for, 352-353

Clobetasol, 287

Clonidine (Catapres, Catapres-TTS). *See* Catapres/Catapres-TTS (clonidine)

Clorpres, 219t

Clotrimazole (Lotrisone). *See* Lotrisone (clotrimazole)

COBRA, 330t-331t

Coffee, 74-75, 83

Cognitive-behavioral therapy, 51

Cognitive decline, sleep apnea as cause of, 300

Colesevelam (Welchol). *See* Welchol (colesevelam)

Colestid (colestipol), 224t, 225

Colestipol (Colestid). *See* Colestid (colestipol)

Colon disorders, 266t, 270-271

Colonic neuropathy, 266t, 270-271

Coma, diabetic, 312

Coma, risk for, 96

Combination or dual-wave bolus, 161

Combination therapy

- bedtime and daytime, 121-123, 151t
- benefits of, 114-115, 357
- for blood pressure control, 216t, 217, 219t, 220, 225-226, 226t
- in case studies, 125-126, 148, 193-194
- for cholesterol control, 224t, 225-226, 226t
- dosage of, 115t
- guidelines for, 119-120
- hypoglycemia risks associated with, 209
- treatment algorithm for, 124f

Complications of diabetes. *See also* Microvascular diabetes complications

- A1C, link to, 202
- causes of, 21, 26-27, 125, 169, 313
- depression as factor in, 48
- diagnosing, 19
- economic aspects of, 327, 345
- emotional aspects of, 46-48, 46t-47t, 64, 319
- exercise and, 90t, 93, 96-98
- family history of, 340-342

Complications of diabetes (*continued*)

- long-term, 46
- managing, 17, 321
- medication for, 237-238
- preventing, 17, 19, 24, 29, 32-33, 51, 63, 87, 180, 203, 236, 254, 327, 342, 345, 355
- reducing, 28, 32, 114
- risk factors for, 52
- short-term acute, 28, 32, 32t
- treating, 14-15
- in type 1 vs type 2 diabetes, 23
- work and, 315

Computer role in diabetes management, 301-310, 306f-309f, 374

Computer software programs, 303-305, 309

Concentration, lack of, 48, 293t, 295

Conditions associated with diabetes, 21t, 22

Congestive heart failure

- medication restrictions in event of, 110, 113
- risk factors for, 113t
- sleep apnea as factor in, 293, 296, 300

Constipation, 59f, 265, 270-271

Continuous glucose monitoring (CGM)

- basal rate testing through, 134
- benefits of, 41-42, 138, 142-143, 145t, 151, 169-170, 172f, 172-174, 186, 250, 357
- case studies, 189-190
- computer data collected from, 301
- diabetes warranty program, component of, 56
- education concerning, 360
- exercise results, measuring through, 146
- expenditures on, 345
- insurance coverage of, 326
- overview of, 37
- results, reviewing with doctor, 58t, 60
- start-up period for, 174-175

Continuous glucose monitors, 147-148, 160, 169-170, 171f, 174-177, 180-184, 190, 193, 197-198, 302-303, 357, 375

Continuous positive airway pressure (CPAP), 297-300, 297f-298f

Convulsions, risk for, 206

COPD (chronic obstructive pulmonary disease), 135

Coreg (carvedilol), 219t, 221

Corgard (nadolol), 219t

Cornea, 252

Coronary artery disease, mortality due to, 211-212

Correction boluses, 154t, 156-157, 164-165, 176

Correction factor

- importance of, 151
- insulin pump programming with, 154, 157-158, 160, 162
- overview of, 140-141, 156
- use, examples of, 177, 184, 195-196

Cortisol, 201

Corzide, 219t

Counseling, 51

Covera-HS (verapamil), 219t

Cozaar (losartan), 219t, 247t

CPAP (continuous positive airway pressure), 297-300, 297f-298f

Creatinine, 240-241

Creatinine clearance, 109

Crestor (rosuvastatin), 224t, 248t

Critically ill, diabetes management for, 337-338

C-sections, 25

CTS (carpal tunnel syndrome), 92, 261-262

Cure, potential for diabetes, 22

Cymbalta (duloxetine), 233

DASH (Dietary Approaches to Stop Hypertension) diet, 82

Davidson, Mayer, 14-15

Dawn phenomenon
 case studies of, 148, 184-186, 185f, 196, 196f
 counteracting with insulin pump therapy, 148, 153-154, 157, 159-160

DCCT. *See* Diabetes Control and Complications Trial (DCCT)

Dehydration, 95-97

Delayed stomach emptying. *See* Gastroparesis

Delivery, problems with, 25

Deltec CozMo (Smiths Medical) (insulin pump), 166f

Dental examination, 56f, 279t, 280-282, 281t

Dentures, 279t, 280

Department of Transportation, 335t

Depression, 46t, 46-48, 50-51, 293t, 295

Dermatitis herpetiformis, 270

Dermopathy, 283, 283t, 286-287, 287f

DESA (Diabetes Exercise and Sports Association), 368

Designer insulin analogues, 357

Desipramine, 232

Detemir (Levemir). *See* Levemir (detemir)

Dexcom, Inc., 375

Dexcom STS CGM System, 147, 171f, 302

DIA (duration of insulin action), 162-163

DiaBeta (glyburide), 94, 105t, 273

Diabetes
 adult-onset, 20t, 22, 272
 age at onset, 20-21, 21t
 associations, 368
 complications of
 macrovascular, 28, 29, 31, 32, 211, 238, 239, 248, 249, 255, 263, 357
 end-stage, 345
 defined, 346
 directories, 367
 emotional aspects of, 37, 39, 45-54, 46t, 198, 313-314, 317, 319-320, 363-364
 in ethnic groups
 African Americans, 21t, 22, 28t, 348t
 Asian Americans, 21t, 22, 28t, 348t
 Hispanics, 21t, 22, 28t, 348t
 Native Americans, 21t, 22, 28t, 348t
 Pacific Islanders, 21t, 22, 28t, 348t
 gestational. *See* Gestational diabetes
 history sheet, 58, 59f-60f
 information sources, 369
 job description, impact on, 316
 juvenile-onset, 20
 management
 economic aspects of, 50, 327, 345
 environmental challenges to, 50
 legal aspects of, 326-329, 331-338
 musculoskeletal system, impact on, 259-264
 online stores, 372
 police, 49, 54
 prevention of, 345-355
 products, 372-376
 psychological aspects of, 369
 publications
 books, 373
 magazines, 372
 risk factors for
 gestational, 26
 type 2, 28t, 347, 348t
 in school settings, 335-336, 336t, 369
 screening tests. *See* Screening tests
 self-advocacy, for patients with, 17-19, 35, 42, 103, 325-326, 329, 338, 358-359, 368
 stable, 22
 support groups, 54
 symptoms of
 glucose level as, 25t, 32t

Diabetes, symptoms of (*continued*)

- at onset, 11-12, 311-312
- type 2 diabetes, 23, 340
- travel resources, 371
- treatment for. *See* Treatment for diabetes
- type 1. *See* Type 1 diabetes
- type 2. *See* Type 2 diabetes
- veterans with, 313-317, 320
- warranty program, 55, 56f-57f, 58, 65, 357-358
- werewolves, 46
- in wartime, 311-313
- in the workplace, 368

Diabetes Control and Complications Trial (DCCT), 28-32, 30f, 202, 206, 229, 239, 243, 257, 323-326

Diabetes Exercise and Sports Association (DESA), 368

Diabetes Forecast (magazine), 372

Diabetes Health (magazine), 372

Diabetes Mall (website), 370

Diabetes Outcome Progression Trial, A (ADOPT), 105-106, 106f

Diabetes Prevention Program (DPP), 346t, 347-351

Diabetes Prevention Trial for Type 1 Diabetes (DPT-1), 352-353

Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication (DREAM), 346t, 349

Diabetes Self-Management (magazine), 372

Diabetic Chef, The (Chris Smith), 360

Diabinese (chlorpropamide), 94, 105t, 273

DIA (duration of insulin action), 162-163

Diagnosis of diabetes

- criteria for, 25-26
- dermatologist role in, 283, 286, 288
- personal accounts, 12, 312
- presymptomatic, 124
- workplace impact of, 316

Dialysis

- causes of, 87
- exercise for patients on, 98
- expenditures on, 345
- fear of, 48, 237
- preventing need for, 237f, 242, 250

Diarrhea, 265, 269, 271, 273-274

Diastolic blood pressure, 244, 245t

Dicyclomine (Bentyl). *See* Bentyl (dicyclomine)

Diet. *See also* Portion sizes

- as cholesterol control strategy, 223
- consistency in, 155
- counseling concerning, 322f
- determining appropriate, 67-68
- education concerning, 360, 362
- glucose levels, adjusting through, 38t, 77
- healthy, 343t
- high-fiber, 271, 274, 347
- high-protein, 249
- information, conflicting on, 68
- insulin dosage, determining based on, 141-142, 143t, 151
- low-calorie, 313
- low-fat, 274
- low-protein, 244t, 247-248, 250
- managing, 13, 49, 120, 121t, 124
- modifying, 188, 266, 342-343, 347, 350-351
- nutrition knowledge vs food preferences, 67
- online information on, 369
- oral health, impact on, 279, 279t
- publications on, 373
- soda, 75
- stumbling blocks to good, 46, 50
- of type 2 diabetes patients, 21t, 24f

Dietary Approaches to Stop Hypertension (DASH) diet, 82

Diflucan (fluconazole), 266, 268, 286

- Digestion
 - glucose regulation during, 116f, 116-117, 161
 - rate of, 136
- Digoxin (Lanoxin). *See* Lanoxin (digoxin)
- Dilacor (diltiazem), 219t
- Dilantin (phenytoin), 269
- Dilia XT (diltiazem), 219t
- Diltiazem
 - Cardizem. *See* Cardizem (diltiazem)
 - Cartia XT. *See* Cartia XT (diltiazem)
 - Dilacor. *See* Dilacor (diltiazem)
 - Dilia XT. *See* Dilia XT (diltiazem)
 - HCl. *See* Cardizem CDE (diltiazem HCl)
 - Tiazac. *See* Tiazac (diltiazem)
- Diovan HCT, 219t
- Diovan (valsartan), 219t, 247t, 350
- Diphenoxylate/atropine (Lomotil). *See* Lomotil (diphenoxylate/atropine)
- Dipyridole, 287
- Direct renin inhibitors, 218, 219t, 220
- Disability
 - discrimination, 333-335
 - hidden, diabetes as, 316
 - legal definition of, 334-335
- Discouragement, 50
- Disetronic Medical Systems, 375
- Disposable adhesive pumps, 165
- Diupres, 219t
- Diuretic
 - ACE inhibitor combinations, 219t
 - ARB combinations, 219t
 - beta-adrenergic blocker combinations, 219t
- Diuril (chlorothiazide), 219t
- Dizziness, 311
- Doctor
 - appointments, setting, 61-62
 - as counselor, 60
 - evaluating and selecting, 14, 18-19, 325
 - exercise, discussing with, 58t
 - office, glucose testing at, 36-37
 - patient communication, 61, 310, 362-364
 - patient relationship, 18-19, 41, 60
 - questions for, 18-19, 57, 58t, 60, 61, 62, 63
 - role in patient advocacy, 326, 329
 - time, adequate with, 61-62
 - visits
 - frequency of, 55-58
 - preparation for, 63, 65
 - successful, factors in, 60-63
 - tests and procedures during, 56f, 58, 60
- Domperidone (Motilium). *See* Motilium (domperidone)
- Donnatal (belladonna/phenobarbital), 271
- Doxazosin (Cardura). *See* Cardura (doxazosin)
- DPP-4
 - enzyme, 118
 - inhibitors (incretin enhancers), 104, 114, 115t, 124, 124f, 126
- DPP (Diabetes Prevention Program), 346t, 347-349, 350-351
- DTP-1 (Diabetes Prevention Trial for Type 1 Diabetes), 352-353
- DREAM (Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication), 346t, 349
- Driver's license, avoiding loss of, 331-332
- Driving
 - hypoglycemia while, 64, 209-210
 - trucks, 335t
- Drugs. *See* Medications
- DrugStore.com, 372
- "Dry labbing," 40-41, 197-198
- Dry mouth (xerostomia), 277, 277t-278t

Duetact (pioglitazone/glimepiride), 115t
 Dulcolax (bisacodyl), 271
 Duloxetine (Cymbalta). *See* Cymbalta (duloxetine)
 Duodenum, 268
 Dupuytren's contracture, 260-261
 Duration of insulin action (DIA), 162-163
 Dyazide, 219t
 Dyes, receiving, 110
 Dymelor (acetohexamide), 105t
 DynaCirc (isradipine), 219t
 Dyspepsia, 268

Eating out, tips for, 67-68
 Economic aspects of diabetes management, 50, 327, 345
 Edelman, Ingrid, 16, 66f
 Edelman, Steven V.
 in case studies, 226-227, 257-258, 263-264, 264f, 282
 diabetes diagnosis and aftermath, 11-15
 Internet information provided by, 368
 marriage and family of, 16-17, 43f, 66f, 127f-128f, 228f, 344f, 353-354, 354f, 355f-356f
 medical history of, 11-15, 59f-60f
 medicine, study of, 15-16, 237
 EDIC (Epidemiology of Diabetes Interventions and Complications), 323-324
 EEOC (Equal Employment Opportunity Commission), 333-334
 Elavil, 269
 Elderly
 abuse of, 337
 hyperglycemia in, 32, 32t
 hypoglycemia in, 208-209
 Eli Lilly and Company, 371, 375
 Emotional aspects of diabetes, 37, 39, 45-54, 46t, 198, 313-314, 317, 319-320, 363-364
 Employee Retirement Income Security Act (ERISA), 330t
 Enalapril (Vasotec). *See* Vasotec (enalapril)
 End-stage
 diabetes complications, 345
 renal disease, 237, 242-243
 Enduron (methylothiazide), 219t
 Enteric neuropathy, 265, 269, 274
 Environmental challenges to diabetes management, 50
 Enzyme pills, 272
 Epidemiology of Diabetes Interventions and Complications (EDIC), 323-324
 Epinephrine (adrenalin), 185, 200
 Eprosartan (Teveten). *See* Teveten (eprosartan)
 Equal Employment Opportunity Commission (EEOC), 333-334
 ERISA (Employee Retirement Income Security Act), 330t
 Eruptive xanthomas, 283t, 288, 289f
 Erythromycin, 267
 Esidrix (hydrochlorothiazide), 219t
 Esomeprazole (Nexium). *See* Nexium (esomeprazole)
 Esophagus, 265-266
 Ethnic breakdown of diabetes patients, 21t, 22, 26, 28t, 348t
 Eucerin, 290
 Calming Cream, 290
 Exenatide (Byetta). *See* Byetta (exenatide)
 Exercise
 aerobic, 96
 as antidepressant, 51
 blood pressure control through, 82
 as cholesterol control strategy, 223
 chronic health problems, reducing through, 85-86
 clinical trials on, 347, 349
 diabetes prevention through, 346, 351
 discussing with doctor, 58t
 glucose control through, 24f, 85, 87-88, 124, 172, 178, 309
 glucose monitoring and, 94, 143, 145t, 146-147, 147t
 importance of, 45, 85-87, 102

Exercise (*continued*)

- insulin dosage adjustment based on, 143, 146-147, 147t, 151
- mental health, impact on, 85
- motivation for, 45-46, 101
- obstacles to, 49
- postmeal, 38t
- prebreakfast, 100
- programs, 359
- risks and precautions, 89, 90t, 93-102
- sex as, 204
- social support role in, 49, 53-54, 101
- starting program of, 88-90, 90t
- timing of, 100
- types of, 90-93
- vigorous vs moderate, 89, 90t, 96
- walking as, 38t, 89-91, 96-97, 101-102, 354
- at workplace, 343

Exocrine insufficiency, 266t, 271-272

Extended or square-wave bolus, 161

Exubera, 134-135

Exubera device, 134f

Eye

- anatomy of, 252
- disease (diabetic retinopathy)
 - asymptomatic, 213
 - background (diabetic retinopathy), 252-253, 305
 - in case studies, 125
 - causes and risk factors for, 31, 42, 256-257
 - continuous glucose monitoring for patients with, 169
 - diabetes management for patients with, 31
 - defined (diabetic retinopathy), 256
 - diagnosis of, 125, 249
 - exercise and, 90t, 97-98, 99t
 - focus on, 211
 - glucose levels, excessive as cause of, 21, 27, 254
 - high blood pressure as factor in, 238, 244-245
 - insulin pumps for patients with, 153
 - medications for, 255-257
 - as microvascular diabetes complication, 28, 238
 - preventing, 19, 31, 202, 257, 357
 - proliferative (diabetic retinopathy), 14, 99t, 237, 253, 253f, 256f
 - treatment for, 59
- examination, 56f, 63, 251, 254, 257-258
- hemorrhages, 257-258
- injuries, 97-98
- reading vision, impact on, 253f

Ezetimibe

- simvastatin, in combination with. *See* Vytorin (ezetimibe/simvastatin)
- Zetia. *See* Zetia (ezetimibe)

Facial structure and sleep apnea, 293, 294f, 296

Facter, Ken, 16, 211, 211f, 228f

Falls, frequent in elderly, 32, 32t

Family history

- of atherosclerosis, 214
- of diabetes, 21t, 23, 26, 60f, 188, 340-343, 348t
- of heart disease, 213t

Famotidine (Pepcid). *See* Pepcid (famotidine)

Fasting blood glucose (FBG) test, 25-26, 25t

Fatigue

- in celiac disease, 270
- in depression, 47
- as diabetes onset symptom, 11, 311
- exercise as antidote to, 88, 101
- glucose control, poor as cause of, 32, 32t
- sleep apnea as cause of, 294, 296, 300

Fats. *See also* Saturated fats; Trans fats

- absorption
 - blocking, 350
 - inadequate of, 270
- bad vs good, 45
- daily budget of, 80t, 84
- intake, reducing, 82, 347
- limitations for, 179
- monounsaturated, 79
- protein and, 77-81, 78f
- use of, 93-94

Fatty liver, 266t, 272-274

FDA (Food and Drug Administration). *See* Food and Drug Administration (FDA)

FDPS (Finnish Diabetes Prevention Study), 346t, 347, 350

Federal Motor Carrier Safety Administration (FMCSA), 335t

Feet

- caring for, 49, 229-236, 284
- circulation to, 234
- examination of, 60
- injuries and ulcers, 99, 229-231, 230f, 233, 235-236, 260, 262
- inspecting, 45, 56f, 99t, 229, 230, 235-236, 262
- joint mobility, limited in, 260
- protecting, 97, 99t

Felodipine (Plendil). *See* Plendil (felodipine)

Female hormones, fluctuating, 24

Fena, Cyndee, 64, 275f

Fenofibrate

- Tricor. *See* Tricor (fenofibrate)
- Lofibra. *See* Lofibra (fenofibrate)
- Triglide. *See* Triglide (fenofibrate)
- Antara. *See* Antara (fenofibrate)

Fetal abnormalities, preventing, 25

Fiber, soluble, 81, 84

Fiber supplements, 270, 271

Fifty 50 Pharmacy, 372

Fingerstick, 39, 40, 170, 171f, 172, 172f, 173, 175, 177, 182

Finnish Diabetes Prevention Study (FDPS), 346t, 347, 350

Flexibility training, 90, 92-93

Flexor tenosynovitis (trigger finger), 59f, 92, 260, 261f, 263-264, 264f

Fluconazole (Diflucan). *See* Diflucan (fluconazole)

Fluid replacement, 95

Fluid retention, 113, 113t

Fluvastatin (Lescol/Lescol XL). *See* Lescol/Lescol XL (fluvastatin)

FMCSA (Federal Motor Carrier Safety Administration), 335t

Food

- absorption, 267, 269
- labels, 76, 81-84
- poisoning, 265

Food and Drug Administration (FDA), 361

- approved for use by
 - 5% lidocaine patch, 233
 - continuous glucose monitoring devices, 175
 - duloxetine (Cymbalta), 233
 - inhaled insulin (Exubera), 134
 - pioglitazone (Actos), 349
 - pramlintide (Symlin), 136
 - weight loss and, not approved by, 138
 - pregabalin (Lyrica), 232
 - sitagliptin (Januvia), 114
- guidelines for receiving approval by
 - combination drugs, 119
- definition of, 18, 115t
- drug dose recommended by, 138
- liver function test required by, 113
- not received approval by
 - drugs for prevention of type 2 diabetes, 189, 350

Food and Drug Administration (FDA), not received approval by (*continued*)
 protein kinase C (PKC) inhibitors, 255
 Rezulin, 354
 under review for approval by
 protein kinase C (PKC) inhibitors, 255
 vildagliptin (Galvus), 115t

Fortamet (metformin), 109t. *See also* Metformin: in combination with
 Fosinopril (Monopril). *See* Monopril (fosinopril)

Free Diabetes Nutrition Teleconferences (website), 369

FreeStyle Navigator CGM System, 171f, 302

Frozen shoulder (adhesive capsulitis), 59t, 92, 262

Fructosamine, 34-35

Fruit, 45, 71t-72t, 81-82, 84
 juice, 65, 72t, 106

Fungal infections, 283t, 285-286

Furosemide (Lasix). *See* Lasix (furosemide)

Gabapentin (Neurontin). *See* Neurontin (gabapentin)

GAD (glutamic acid decarboxylase) antibodies test, 22

Gallstones, 265, 273-274

Galvus (vildagliptin), 114, 115t

Gas, 274

Gasping and choking during sleep, 293-294, 293t

Gastric pacemaker, 267

Gastroenterologist visits, 56f

Gastrointestinal (GI)
 disorders, 265-274, 266t
 tract, anatomy of, 266f
 motility (movement), factors affecting, 274
 reflux disease (GERD), 266

Gastroparesis, 14, 59f, 97, 184-185, 207-208, 266t, 266-267, 315

Gemfibrozil (Lopid). *See* Lopid (gemfibrozil)

Gender breakdown
 in diabetes-related mortality, 212, 212f
 in heart disease, 214

Genetically-engineered insulins, 162

Gestational diabetes
 continuous glucose monitoring (CGM) for, 170
 exercise impact on, 87-88
 managing, 24-25
 overview of, 19, 20t
 publications on, 373
 risk factors for, 26
 screening for, 26
 as type 2 diabetes risk factor, 348t

Gila monsters, 118

Gingivitis, 276, 278

GIP incretin hormone, 114

Glargine (Lantus). *See* Lantus (glargine)

GlaxoSmithKline, 371

Glibenclamide (glyburide), 208

Glimepiride
 Amaryl. *See* Amaryl (glimepiride)
 pioglitazone, in combination with. *See* Duetact (pioglitazone/glimepiride)
 rosiglitazone (Avandaryl), 115t

Glipizide
 extended release. *See* Glucotrol XL (glipizide, extended release)
 Glucotrol. *See* Glucotrol (glipizide)
 in combination with
 metformin. *See* Metaglip (glipizide/metformin)

Glomerular filtration rate (GFR), 109

GLP-1 (glucagonlike peptide-1), 38, 114-118, 116f, 161
 agonists, 209. *See also* Byetta (exenatide)

Glucagon
 as medication, 182, 185, 205-206
 normal vs type 2 diabetes, 117

Glucagon (*continued*)
 overview of, 38
 preventing release of, 136
 production, natural of, 116f, 193, 200

Glucophage (metformin), 94, 106f, 107-109, 109t, 110, 112, 118, 124, 124f, 125-126, 148, 180, 266t, 272, 274, 346, 346t, 348t, 349-351. *See also* Metformin: in combination with

XR (metformin), 108, 109t

Glucose
 levels
 adjusting, strategies for, 37-38, 38t, 41, 172, 177-184, 186-188, 195-196, 198
 before and after meals, 304
 body regulation of, 114, 116f, 116-117
 carbohydrate impact on, 83
 as complication risk factor, 52
 computerized data on, 301-306, 306f-307f, 307-309, 308f-309f
 constant, 173
 controlling
 and cholesterol control, 223
 eye protection through, 254
 and gastrointestinal health, 267-268, 271-272, 274
 goals of, 32-33, 33t, 187
 heart attack rate, reducing through, 214
 heart disease and stroke risk reduction, 214, 222, 254
 importance of, 24-29, 31-35, 51, 77, 323-324, 357
 in institutional settings, 337
 kidney protection through, 242-243, 244t, 250
 neuropathy prevention through, 233, 236, 254
 overnight, 122-123
 record-keeping role in, 301
 through insulin, 139-141, 140f, 150-151, 153-155, 156t, 160-162, 168, 170
 through oral medications, 103, 114, 121t, 124f

depression and, 48

diabetes diagnosis, testing for, 25-26, 25t

discouragement over, 45-46, 50, 51f

exercise impact on, 98-102, 143, 146-147. *See also* Exercise: glucose control through

falling, 173, 180-184, 181f

fluctuating, 20, 22, 137f, 138t, 198, 198f, 305

foods elevating, 69, 71

gastrointestinal disorder impact on, 267

high, consequences of, 21, 23, 26-27, 95, 125, 160, 238, 288

high, factors in, 293

illness impact on, 63-64

immunity, impact on, 234-235

keeping records of, 62

medical stress impact on, 194

monitoring. *See also* Continuous glucose monitoring (CGM); Exercise: glucose monitoring and; Home glucose monitoring (HGM); Record keeping
 A1C (glycosylated hemoglobin) test role in, 33-42, 52
 data interpretation, 361-362
 diabetes prevention, role in, 351
 and driving, 332t
 in hospital, 313
 for hypoglycemia, 107
 as hypoglycemia prevention measure, 206
 motivation for, 47
 in school settings, 336
 through urine testing, 13

periodontal disease impact on, 276, 278

postmeal, 26, 35

premeal, 38, 38t

production of, 107-108

rising, 172, 176-180, 177f, 185f. *See also* Dawn phenomenon

trends, 170, 172-174, 173f, 175f, 176-186, 178f, 301, 303, 305, 309f

in type 2 diabetes, 23

line chart, 305

logbook, 187, 188f-198f, 301, 361-362

Glucose (*continued*)
 meters, 31, 39-40, 50, 51f, 99t, 170, 188, 281t, 302, 306, 328, 332, 345, 351, 373-374, 377t-381t
 muscle cells, taken up by, 87, 93
 regulatory hormones, 38
 tablets, 65, 93, 106, 181, 182, 205
 test strips, 14, 323, 325-326, 328
 Glucotrol (glipizide), 94, 105t, 208
 Glycerol XL (glipizide, extended-release), 105t
 Glucovance (glyburide/metformin), 115t
 Glulisine (Apidra). *See* Apidra (glulisine)
 Glumetza (metformin), 109t
 Glutamic acid decarboxylase (GAD) antibodies test, 22
 Gluten, 269-270
 Glyburide, 148
 in combination with
 metformin. *See* Glucovance (glyburide/metformin)
 DiaBeta. *See* DiaBeta (glyburide)
 Glibenclamide. *See* Glibenclamide (glyburide)
 Glynase PresTab. *See* Glynase PresTab (glyburide)
 Micronase. *See* Micronase (glyburide)
 Glycemic control. *See* Glucose levels: controlling
 Glycogen, using up, 87, 100
 GlycoMark (short-term glycemic control marker), 35
 Glycosylated hemoglobin. *See* A1C (glycosylated hemoglobin)
 Glynase PresTab (glyburide), 105t
 Glyset (miglitol), 95, 110t, 110-112, 112t, 125, 266t, 274, 346
 Grains, 71t, 81-82, 270
 Granuloma annulare, 283t
 Growth
 hormone, 193, 201
 retardation, 270
 Guanabenz (Wytensin). *See* Wytensin (guanabenz)
 Guanfacine (Tenex). *See* Tenex (guanfacine)

H₂ blockers, 268
 Halitosis (bad breath), 278, 278t
 Hand
 diabetic conditions affecting, 259-262
 surgery, 264, 264f
 HDL (high-density lipoprotein, good cholesterol), 221-223, 222t, 224-225, 358
 Headache, 293t
 Health
 care
 access to, 324-329, 330t-331t, 335-338, 358
 economic aspects of, 327, 345
 fairs, 18, 359
 insurance
 cost sharing of, 345
 programs, mandatory, 314
 types of, 330t-331t
 maintenance organization (HMO), 325-326, 338f
 Hearing impairment, 315
 Heart arrhythmias, sleep apnea as factor in, 293
 Heart
 attack
 asymptomatic, 194
 cholesterol goals following, 221-222
 exercise following, 98
 expenditures on, 345
 family history of, 60f, 227
 fatal, 211, 227
 high blood pressure as contributing factor, 244-245
 risk, reducing, 202, 214, 226, 228, 357
 risk factors for, 86, 340-341, 348t, 351, 358
 sleep apnea as factor in, 293, 300
 symptoms of, 99t

Heart (*continued*)

- disease
 - death due to, 212f
 - diabetes as risk factor for, 77, 86, 87
 - examination for, 56f
 - family history of, 60f
 - glucose levels, excessive as cause of, 21, 27
 - markers for, 250
 - prevalence of, 211
 - preventing, 19, 254
 - reducing, 214, 248, 350
 - risk factors for, 213t, 213-215, 222
 - risk vs exercise, 85, 89, 90t
 - warning signs, early of, 212-213
- Heartburn, 59f, 98, 266t, 266-268, 293t, 295
- Helicobacter pylori*, 268
- Hemoglobin (definition), 33
- Henry, Robert, 123
- High blood pressure
 - as circulatory problem factor, 234, 236
 - diabetes, condition associated with, 14, 20, 22, 59f, 357
 - as diabetes risk factor, 26, 348t, 351, 354
 - exercise precautions in event of, 99t
 - as eye disease factor, 244-245
 - as heart attack and stroke risk factor, 244-245
 - as heart disease risk factor, 213, 213t, 215
 - as kidney disease factor, 238, 244-245, 249
 - medication for, 123-125, 194
 - as silent killer, 227
 - sleep apnea as factor in, 292-293, 295-296, 300
- High-density lipoprotein (HDL), good cholesterol, 221-223, 222t, 224-225, 358
- High-fat protein foods, 78-79
- Highway to Health Travel Insurance, 371
- HIPAA, 330t-331t
- HMO (health maintenance organization), 325-326, 338f
- Home Diagnostics, Inc., 374, 380t-381t
- Home glucose monitoring (HGM)
 - vs A1C test results, 35f
 - availability of, 357
 - in case studies, 124, 148, 250, 307
 - data interpretation, 56, 187
 - discussing with doctor, 58t, 60
 - and glycosylated hemoglobin (A1C) test, 14
 - overview of, 36-41
 - pre- and post-exercise, 146
 - during pregnancy, 35
 - pros and cons of, 42, 169, 186
 - purpose of, 142-143, 145t
 - timing of, 130
- Home microalbuminuria test kits, 241
- Hormones. *See also* Incretin hormones; Insulin
 - female, 24
 - gastrointestinal, 271
 - incretin
 - GIP, 114
 - GLP-1. *See* GLP-1 (glucagonlike peptide-1)
 - glucose regulatory, 38
 - growth, 193, 201
 - naturally produced, 196-197, 199-201
 - panic, 292-293
 - stress, 160, 293
- Hospitalizations, depression as factor in, 48
- Humalog (lispro), 59f, 64, 100, 122, 123t, 125, 131t, 132f, 134, 136, 143t, 144f, 145t, 146, 148, 163, 173, 176, 187
- Humulin 70/30, 50/50, 131t
- Hydrochlorothiazide (Esidrix). *See* Esidrix (hydrochlorothiazide)

Hydrogenated fats. *See* Trans fats
 Hydopres, 219t
 Hyoscyamine (Levsin). *See* Levsin (hyoscyamine)
 Hyperglycemia
 in case studies, 149, 275f
 consequences of, 27, 239
 in elderly, 32
 in institutional settings, 337
 minimizing, 38, 170
 nocturnal, 184, 190
 overview of, 95
 preventing, 65, 182
 rebound, 185
 Hypoglycemia
 in case studies, 149, 189-190, 192-193, 207-210
 vs complications of diabetes, 42, 64, 169, 199, 202
 discussing with doctor, 58t
 exercise and, 93-95, 99-100, 99t, 102
 fatal, 207-208
 glucose control without, 357
 incidence of, 29, 31, 59f
 managing, 64-65, 106-107, 204-205, 209-210, 332t
 motor vehicle crashes, as factor in, 64, 209-210
 nocturnal, 192-193, 196, 202
 oral medications as risk factor for, 106-108, 118, 120t, 125
 origins of, 199-202, 206
 preventing, 27, 130, 145t, 151, 159-160, 163, 170, 182, 186, 202-203, 210, 281, 332
 unawareness of, 64, 160, 163, 170, 200-202, 206-207, 332t
 unconsciousness from. *See* Unconsciousness
 at workplace, 335
 Hytrin (terazosin), 219t
 Hyzaar, 219t

 IAMAT (International Association for Medical Assistance to Travelers), 371
 Ibuprofen, 262
 IDC (International Diabetes Center), 368
 IDDM (insulin-dependent diabetes mellitus), 20, 20t
 IDEA (Individuals with Disability Education Act), 335-336
 IDF (International Diabetes Federation), 368
 IFG (impaired fasting glucose), 27f, 346
 IGT (impaired glucose tolerance), 27f, 347
 Illness vs disability, 316
 Imipramine, 232
 Immunity, 234-236, 283, 289
 Immunization requirements, 58t
 Imodium (loperamide), 271
 Impaired fasting glucose (IFG), 27f, 346
 Impaired glucose tolerance (IGT), 27f, 347
 Incretin
 enhancers, 104, 114, 115t, 124, 124f, 126
 hormones, 114-121, 124, 126
 Indapamide (Lozol). *See* Lozol (indapamide)
 Inderal/Inderal LA (Propranolol), 219t
 Inderide LA, 219t
 Individuals with Disability Education Act (IDEA), 335-336
 Indoline diuretics, 219t, 220-221
 Infection
 checking for, 236
 damaged skin as cause of, 289
 medication adjustment for, 234-235
 opportunistic, 284
 resistance, reduced to, 276, 281
 of urinary tract, 32, 32t
 Inframammary candidiasis, 285f
 Infusion sets, 167-168
 Inhaled insulin, 21, 134-136, 375

Injuries

- eye, 97-98
- feet, 99, 229-231, 230f, 233, 235-236, 260, 262
- orthopedic and arthritis, 96
- risk of, reducing, 92

Insulet Corporation, 375

Insulin

- administration and delivery of, 12, 15, 21, 42, 59f, 99, 129-130, 142, 154t, 157.
 - See also* Insulin: injections; Insulin: pens; Insulin: pumps
- algorithms or sliding scales, 139-141, 140f, 150, 151
- attitudes toward, 125
- basal, 131t, 133-135, 146, 148, 151t, 153-154, 154t, 157, 176, 181, 194-195
- correction factors. *See* Correction factors
- deficiency, problems resulting from, 20-21
- dosage
 - basal, 131t, 133-135, 146, 148, 151t, 153-154, 154t, 157, 176, 181, 194-195
 - determining, 41-42, 59f, 63-64, 139-142, 145t, 146, 151, 158-159, 172, 198, 208, 309
- effectiveness of, 158-159, 162-163
- and exercise, 94, 98-101
- expenditures on, 345
- function of, 199
- hypoglycemia associated with excessive, 210
- and hypoglycemia risk, 94
- increasing, 38
- injections
 - alternatives to, 21, 103
 - attitudes toward, 125, 134
 - multiple, 313
 - new medications, 357
 - personal accounts of, 12
 - vs pumps, 157-160
 - at start of treatment, 341
 - subcutaneous, 42
 - time course of action of, 130
- intermediate-acting, 100, 131t, 186
- for LADA patients, 22
- long-acting, 98-99, 131t, 132-134, 142, 148, 158, 181, 191, 195-196, 198, 202-203, 249
- menu, 142, 143t, 151
- oral medications used with, 103, 105, 113, 119-123, 121t, 122t, 123t, 126, 148, 151t
- vs other hormones, 115-116
- pens, 142, 144f, 149-150, 156-157, 181, 303, 375
- premeal, 124f, 139-142, 143t, 145t, 146, 151
- premixed, 122-123, 123t, 136, 142, 191
- production, natural of, 129, 200
- pumps
 - benefits of, 148, 153, 154t, 157-160
 - in case studies, 184-185, 190-191, 207-208
 - computerized data uploaded from, 302
 - devices communicating with, 40
 - expenditures on, 345
 - function of, 99, 153-154
 - hypoglycemia risk and, 94
 - insurance coverage of, 326, 328
 - medication regimens with, 138, 147, 151t, 154-157
 - selecting, 165-168
 - smart, 153, 155, 156t, 160-165, 302, 357
 - suppliers of, 375-376
 - types of, 166f
- rapid-acting, 122, 131t, 132f, 133t, 141-142, 145t, 146t, 153-154, 157, 173, 176, 179, 181, 187, 190-191, 195, 207, 309
 - analogue, 59f, 130, 132, 191, 249
- regimens, 147-151, 151t
- regular, 59t, 130, 131t, 132, 132f, 133t, 136, 139, 141, 144f, 145t, 146, 146t, 149, 162, 305, 309
- as required therapy, 21t
- resistance to, 23-24, 24f, 88, 94, 100, 104, 111, 126, 153, 18-184, 195-196, 272, 293, 313, 345, 348t
- secretagogues. *See* Nonsulfonylurea insulin secretagogues; Sulfonylureas (SFUs)

Insulin (*continued*)

- sensitivity factor. *See* Correction factor
- sensitivity to, 87, 91, 101, 148, 158, 166
- sensitizers, 94, 104, 111-114, 113t, 126, 349
- short-acting, 98-99, 100, 131t, 181, 309
- time course of action of, 130, 131t, 132f
- timing of, 38t, 145t, 156, 160, 163-164, 194, 199, 207
- for type 2 diabetes patients, 23, 125-126, 180, 341-342
- types of, 130, 132-135, 180-181
- Insulin-dependent diabetes mellitus (IDDM), 20, 20t
- International Association for Medical Assistance to Travelers (IAMAT), 371
- International Diabetes Center (IDC), 368
- International Diabetes Federation (IDF), 368
- Internet, 303-304, 310, 367-372
- Intestinal motility (movement), abnormalities in, 265, 268, 271, 274
- Irbesartan (Avapro). *See* Avapro (irbesartan)
- Irritability, 293t, 295
- Irritable bowel syndrome, 265, 270-271
- Ischemia, 98
- Isophane (NPH). *See* NPH (isophane)
- Isoptin SR (verapamil), 219t
- Isradipine (DynaCirc). *See* DynaCirc (isradipine)
- Itchy skin, 289-290
- Itraconazole (Sporanox). *See* Sporanox (itraconazole)

- JAN (Job Accommodation Network), 368-369
- Janumet (sitagliptin/metformin), 115t
- Januvia (sitagliptin), 114, 115t, 124-125
- Jaundice, 273
- Jaw surgery, 299
- JDRF (Juvenile Diabetes Research Foundation International), 368
- Job Accommodation Network (JAN), 368-369
- Job description, diabetes impact on, 316
- Job discrimination, 314-317, 333-335
- Joint mobility
 - increasing, 96
 - limited, 59f, 259-260, 260f, 264
- Joslin Diabetes Center, 370
- Joslin Diabetes Clinic, 16
- Juice, 65, 72t, 106, 342-343
- Juvenile Diabetes Research Foundation International (JDRF), 368

Keratolytics, 286

- Kerlone (betaxolol), 219t
- Ketoacidosis, 278
- Ketoconazole (Nizoral). *See* Nizoral (ketoconazole)
- Ketones, 64, 95
- Ketosis, 95
- Kidney
 - damage, 51, 218
 - dialysis. *See* Dialysis
 - disease (diabetic nephropathy). *See also* Nephropathy
 - asymptomatic, 213
 - causes of, 169
 - checking for, 63
 - death due to, 15
 - as diabetes complication, 14, 28, 42
 - diagnosis of, 59f, 249
 - exercise and, 98
 - exercise precautions for patients with, 90t
 - fear of, 319
 - focus on, 211
 - glucose levels, excessive as cause of, 21, 27
 - high blood pressure as contributing factor, 244-245
 - insulin pumps for patients with, 153
 - as microvascular complication, 28

Kidney, disease (*continued*)
 overview of, 237
 preventing, 19, 31, 202, 239, 250, 357
 protein, limiting in event of, 179
 screening and detection of, 238, 239-242, 250
 treating and managing, 237-238, 239, 240, 242-249, 244t, 250
 failure, 19, 27, 226, 237, 337
 function
 and oral medications, 120t, 124
 testing, 109-110
 worsening, skin conditions linked to, 289, 290
 transplant, 243, 250, 315
 Konsyl, 270

 Lactic acid, 290
 LADA (Latent Autoimmune Diabetes in Adults), 21-22
 Lanoxin (digoxin), 110
 Lantus (glargine), 59f, 100, 122, 125, 131t, 132-133, 132f, 135, 144f, 147-148, 158-159, 176, 180-181, 187, 193-194, 202-203, 249
 Laser surgery and therapy, 14, 237, 252-253, 255-258
 Lasix (furosemide), 110
 Latent Autoimmune Diabetes in Adults (LADA), 21-22
 Laxatives, 271
 LDL (low-density lipoprotein, bad cholesterol), 81, 221-222, 222t, 223, 225-226, 244t, 248, 358
 Legal aspects of diabetes management, 326-329, 331-338
 Lescol/Lescol XL (fluvastatin), 224t, 248t
 Levemir (detemir), 100, 122, 125, 131t, 132f, 133, 135, 141, 144f, 148, 150, 158-159, 181, 195, 202
 Levsin (hyoscyamine), 271
 Lexxel, 219t
 Life-extending, 51
 Life expectancy of diabetes patients, 15-16, 313-314, 319-320
 LifeScan, 374, 380t
 Lifestyle
 active, 354
 busy, 50
 flexible, 157-158
 healthy, 51
 insulin regimen based on, 151
 modification of, 107, 124, 124f, 156t, 188-189, 223, 228, 247, 266, 319-320, 342-343, 345-353, 355
 Lipid
 levels, high
 dermatological symptoms of, 288
 vs exercise, 90t
 panel, 223, 227, 358
 Lipitor (atorvastatin), 59f, 224t, 225, 227, 248t
 Liquids, glucose control through, 205
 Lisinopril
 Prinivil. *See* Prinivil (lisinopril)
 Zestril. *See* Zestril (lisinopril)
 Lispro (Humalog). *See* Humalog (lispro)
 Liver
 cancer of, 272
 disorders of, 266t, 272, 289-290
 function
 and oral medications, 120, 124
 test, 113
 glucose production, role in, 107-108
 Lofibra (fenofibrate), 224t, 225
 Lomotil (diphenoxylate/atropine), 271
 Loperamide (Imodium). *See* Imodium (loperamide)
 Lipid (gemfibrozil), 224t, 225
 Lopressor HCT, 219t
 Lopressor (metoprolol), 219t
 Losartan (Cozaar). *See* Cozaar (losartan)
 Lotensin (benazepril), 219t, 246t
 Lotrel, 219t
 Lotrisone (clotrimazole), 285

Lovastatin
 Mevacor. *See* Mevacor (lovastatin)
 Altocor. *See* Altocor (lovastatin)
 Lovastatin/niacin ER (Advicor). *See* Advicor (lovastatin/niacin ER)
 Low-density lipoprotein (LDL), bad cholesterol, 81, 221-223, 222t, 225-226, 244t, 248, 358
 Lozol (indapamide), 59f, 219f, 220-221
 Lucentis (ranibizumab), 255
 Lyrica (pregabalin), 232

Macintosh computers, 302
 Macroalbuminuria, 240t
 Macrovascular disease, risk factors for, 211
 Macugen (pegaptanib sodium), 255
 Macular
 degeneration, 180
 edema, 257
 Making the Connection programs, 17-18, 362-364, 365f
 Malabsorption, 269
 Mandibular advancement device, 299, 299f
 Margarine, 68, 81, 83
 Mavik (trandolapril), 219t, 246t
 Maxzide, 219t
 Meal
 modifications, 75-76, 80
 planning, 58t
 Meat, 77-79, 78f, 81, 247-248
 Median nerve, compression of, 261
 Medical
 chart, 55
 devices
 access to, 19, 43
 for home glucose monitoring, 34f, 39-40. *See also* Continuous glucose monitors; Glucose: meters
 examination, 333
 history, 58, 59f-60f
 reminders and alerts, 160, 163-164, 166
 stress impact on glucose levels, 194
 Medic Alert bracelet or necklace, 99t
 Medicare, 327
 Medications. *See also* Oral: medications
 access to, 19, 43
 affordability of, 50
 antidepressants, 51, 232-233, 269
 attitude toward, 52
 for blood pressure control, 82
 diabetes prevention, role in, 351, 354-355
 guidelines for, 119-123, 120t
 information concerning, 61
 insurance coverage of, 326-328
 prescription, 57-58, 61, 373
 information concerning, 61, 373
 regimen, developing, 216t, 217. *See also* Insulin: regimens
 side effects of, 51, 216t, 217, 266t, 269, 273-274, 277, 315
 studying and evaluating, 346, 348-350
 testing and approval of, 18, 119
 MedicineNet (website), 370
 MediCompass software, 309
 Medline Plus, 367
 Medtronic Diabetes, 376
 Medtronic Guardian RT (glucose meter), 302
 Memory loss, 293t, 295
 Mental
 health, exercise impact on, 85
 impairment in elderly, 32, 32t
 Merck, 371
 Metabolism of diabetic vs nondiabetic individuals, 38
 Metaglip (glipizide/metformin), 115t

Metamucil, 270-271

Metformin
in combination with
glipizide. *See* Metaglip (glipizide/metformin)
GLP-1 agonists, 209
glyburide. *See* Glucovance (glyburide/metformin)
pioglitazone. *See* Actoplus Met (pioglitazone/metformin)
rosiglitazone. *See* Avandamet (rosiglitazone/metformin)
sitagliptin. *See* Janumet (sitagliptin/metformin)
sulfonyleureas, 209
Fortamet. *See* Fortamet (metformin)
Glucophage. *See* Glucophage (metformin)
Glucophage XR. *See* Glucophage XR (metformin)
Glumetza. *See* Glumetza (metformin)
Glucovance. *See* Glucovance (glyburide/metformin)

Methylothiazide (Enduron). *See* Enduron (methylothiazide)

Methyldopa (Aldomet). *See* Aldomet (methyldopa)

Metoclopramide (Reglan). *See* Reglan (metoclopramide)

Metoprolol
Lopressor. *See* Lopressor (metoprolol)
Toprol-XL. *See* Toprol-XL (metoprolol)

Metrika, Inc., 374

Mevacor (lovastatin), 224t, 248t

Micardis HCT, 219t

Micardis (telmisartan), 219t, 247t

Micral test strips, 241

Microalbumin test, 56f

Microalbuminuria, 153, 216, 218, 226, 239-242, 240t, 245-247, 249-250

Microangiopathy, 251

Micronase (glyburide), 94, 105t, 208, 273

Microvascular diabetes complications, 28-29, 31-32, 211, 238-239, 248-249, 255, 263, 357

Miglitol (Glyset). *See* Glyset (miglitol)

Military, diabetes in, 311-313

Milk, 71t, 72t, 74-75, 79, 81, 205

Milk of magnesia, 271

MiniMed
Guardian CGM System, 171f
Paradigm Insulin Pump and CGM Kit, 166f, 171f

Minipress (prazosin), 219t

Minizide, 219t

Miyares, Urban, 311-321

Moduretic, 219t

Moexipril (Univasc). *See* Univasc (moexipril)

Moisturizers, 289-290

Monopril (fosinopril), 59f, 219t, 246t

Monopril HCT, 219t

Monotherapy, 123-125, 218

Monounsaturated fats, 79

Mortality
diabetes-related causes of
depression as factor in, 48
heart disease, 211-212, 212f, 227
kidney disease, 237
overview of, 15-16
exercise impact on, 85-86, 96

Motilium (domperidone), 267

Motivation, 13, 18, 42, 45-54, 358-359, 363-365, 368

Motor vehicle crashes
hypoglycemia as factor in, 64, 209-210
sleep apnea as factor in, 300

Mouth
anatomy of, 292f
disorders of, 266t, 268, 275-278, 278t
ulcers of, 277

Mouthwashes, 280

Muscle

- cells, glucose taken up by, 87, 93
 - diabetic conditions affecting, 263
 - infarction, 263
- Musculoskeletal system, diabetes impact on, 259-264
- MyTCOYD* newsletter, 361-362, 363f

Nadolol (Corgard), 219t

Nail, trimming, 235, 236f, 284

Nasal anatomy, 292f

NASH (nonalcoholic steatohepatitis), 272

Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) study, 350

Nateglinide (Starlix). *See* Starlix (nateglinide)

National Diabetes Education Initiative (NDEI), 368

National Diabetes Education Program (NDEP), 368

National Eye Institute (NEI), 252

National Information Center for Children, 369

National Information Center for Children and Youth with Disabilities, 336t

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), 367, 370

National Institutes of Health, 28, 254, 323, 347, 352

Nausea, 118, 137, 139, 265, 267, 273-274, 311-312

NAVIGATOR (Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research) study, 350

NDEI (National Diabetes Education Initiative), 368

NDEP (National Diabetes Education Program), 368

Necrobiosis lipoidica diabetorum (NLD), 283, 283t, 287-288, 288f, 290

NEI (National Eye Institute), 252

Nephropathy, 28, 90t, 238, 263. *See also* Kidney: disease

Nerve disease (neuropathy). *See also* Peripheral: neuropathy

- causes of, 42

- diagnosing, 231, 232f

- exercise precautions in event of, 90t, 99t

- focus on, 211

- gastrointestinal, 265, 266t, 269-271, 274. *See also* Gastroparesis

- glucose levels, excessive as cause of, 21, 27, 125, 229, 249

- as long-term diabetes complication, 28, 169

- as microvascular diabetes complication, 28, 238

- oral, 278, 278t

- overview of, 229-231, 236

- painful diabetic, 231-233

- preventing, 19, 31, 229, 233

- reducing, 202

- treating, 232-233

- as workplace challenge, 315

Neurontin (gabapentin), 232, 269

Neuropathic

- arthropathy (Charcot's joint), 230-231, 231f, 263

- ulcers, 283t

Neuropathy, peripheral. *See* Peripheral: neuropathy

Neutrogena, 290

Nexium (esomeprazole), 268

Niacin extended-release (Niaspan). *See* Niaspan (niacin extended-release)

Niacin (nicotinic acid), 224t

Niaspan (niacin extended-release), 224t, 225

Nicardipine (Cardene). *See* Cardene (nicardipine)

NIDDK (National Institute of Diabetes and Digestive and Kidney Diseases), 367, 370

NIDDM (non-insulin-dependent diabetes mellitus), 22

Nifedipine

- Adalat. *See* Adalat (nifedipine)

- GITS (Procardia XL). *See* Procardia XL (nifedipine GITS)

Night-time eating, 46, 72

Nimodipine (Nimotop). *See* Nimotop (nimodipine)

Nimotop (nimodipine), 219t

Nisoldipine (Sular). *See* Sular (nisoldipine)

Nizatidine (Axid). *See* Axid (nizatidine)

Nizoral (ketoconazole), 268, 285

NLD (necrobiosis lipoidica diabetorum), 283, 283t, 287-288, 288f, 290

Nocturia (night-time urinating), 293t, 295

Nonalcoholic steatohepatitis (NASH), 272

Nondiabetics, eating and diet of, 37-39

Non-insulin-dependent diabetes mellitus (NIDDM), 22

Nonprescription medications, 224t

Nonsulfonylurea insulin secretagogues, 104, 107, 346, 350

Normoalbuminuria, 240t

Norvasc (amlodipine), 219t

Novartis, 371

Novolog (aspart), 59f, 64, 100, 122, 123t, 125, 131t, 132f, 134, 136, 141, 143t, 144f, 145t, 146, 149-150, 163, 173, 176, 187, 190, 195-196

Novolog Mix 70/30, 149-150, 191

Novo Nordisk Inc., 375

NPH (isophane), 100, 122, 125, 131t, 132f, 144f, 147-150, 181, 186, 192-193, 196, 305, 309

Nursing home care of diabetes patients, 337-338

Nutrition. *See* Diet

Nutrition Data (website), 369

Nystatin, 266, 268

Obesity. *See also* Overweight condition

- in case studies, 125-126, 150, 339-342
- in children and teens, 340, 343
- conditions associated with, 273
- defined, 69, 70t
- as diabetes risk factor, 272, 274, 348t
- as sleep apnea risk factor, 293, 293t, 296

Occupational therapy, 260

Octreotide (Sandostatin). *See* Sandostatin (octreotide)

OGTT (glucose tolerance test), 25t, 26, 347

Oils, 79

- olive, 79, 81

Olmesartan (Benicar). *See* Benicar (olmesartan)

Omacor (omega-3-acid ethyl esters), 224t

Omega-3, 81

Omeprazole (Prilosec). *See* Prilosec (omeprazole)

Omeprazole/sodium bicarbonate (Zegerid), 268

OmniPod (insulin pump), 165, 165f

Onset of diabetes, age at, 20-21, 21t

Optic nerve, 252

Oral

- anatomy, 292f
- fungal infection (candidiasis), 266, 277-278, 285f
- glucose tolerance test (OGTT), 25t, 26, 347
- hygiene, 278-282
- medications
 - blood level testing for patients on, 37
 - combination therapy. *See* Combination therapy
 - diabetes prevention, role in, 350
 - dosage, determining, 105t, 198
 - effectiveness of, 22-23, 24f, 104-105, 120-121, 121t, 180
 - vs exercise, 88
 - expenditures on, 345
 - glucose levels, high, adjusting for, 38, 38t
 - guidelines for, 119-123, 120t
 - hypoglycemia risk resulting from, 64, 94-95
 - new, 357
 - overweight condition, for patients with, 102t, 125
 - selecting, 124-125
 - sick-day rules and, 64
 - side effects of, 105-106
 - steroids, 262
 - studying and evaluating, 348-350
 - for type 2 diabetes, 21t
 - types of, 103-114
 - neuropathy, 278, 278t

Organ damage, 26-27

Organizations, 367-368. *See also* Taking Control of Your Diabetes (TCOYD)

Orinase (tolbutamide), 94, 105t, 273

Orlistat (Xenical). *See* Xenical (orlistat)

Orthostasis, 220

Osteoarthropathy (Charcot's joint), 230-231, 231f, 263

Osteoporosis, 113t

Overweight condition. *See also* Obesity

- in case studies, 188, 191
- defined, 69, 70t
- as diabetes risk factor, 26, 188, 348t, 354
- exercise with, 89, 91
- as heart disease risk factor, 213t, 215
- oral medication for patients with, 120t, 125
- and sleep apnea, 291

Painful diabetic neuropathy (PDN), 231-233

Pain medications, 269

Pancreas

- antibody attacks on, 20, 21
- disorders of, 266t, 271-272
- function of, 129, 147-148, 271-272
- mimicking, 153-154, 157

Panic hormones, 292-293

Pantoprazole (Protonix). *See* Protonix (pantoprazole)

Pasta, 76-77

Patient education

- harmful beliefs, countering through, 51
- importance of, 17-19, 103, 124, 365
- organizations promoting, 17-19, 359-365, 368
- post-diagnosis, 12
- self-education, 42-43, 63, 318-319, 338, 357-359
- for young people, lack of, 13

Patient noncompliance, 363-364

Patient resources, 310

PDN (painful diabetic neuropathy), 231-233

Pedometer, 101, 343t

Pegaptanib sodium (Macugen). *See* Macugen (pegaptanib sodium)

Pentoxifylline, 287

Pepcid (famotidine), 266, 268

Perfectionism, 49

Perindopril (Aceon). *See* Aceon (perindopril)

Periodontal disease, 275-276, 276t, 282

Periodontitis, 276, 278, 280

Peripheral

- arterial disease, 97
- neuropathy, 14, 60, 97, 99t, 153, 213, 254, 262, 265, 269

Peristalsis, 267

Pfizer, 371, 375

PFT (pulmonary function test), 135

Pharmaceutical company websites, 371

Pharyngeal (throat) anatomy, 292f

Phenobarbital/belladonna (Donnatal). *See* Donnatal (belladonna/phenobarbital)

Phenytoin (Dilantin). *See* Dilantin (phenytoin)

Physical

- capacity, 87
- therapy, 260, 262-263

Pinprick sensation, testing, 231

Pioglitazone (Actos). *See* Actos (pioglitazone)

Pioglitazone/glimepiride (Duetact). *See* Duetact (pioglitazone/glimepiride)

Pioglitazone/metformin (Actoplus Met), 115t

Pituitary gland, 201

PKC beta protein, 256-257

PKC (protein kinase C) inhibitors, 255

Placebos, 348, 349

Plaque disease, 275-276, 276t

Plendil (felodipine), 219t

Podiatry for diabetic patients, 16, 56f

Polonsky, Bill, 37

Portion sizes

- cheese, 79
- glucose levels, impact on, 50
- paying attention to, 45
- protein, 78, 84
- strategies for controlling, 67, 77

Postmenopausal women, resistance training in, 92

Post-traumatic stress disorder, 315

Potassium levels, high in blood, 218, 245-246

Pramlintide (Symlin). *See* Symlin (pramlintide)

Prandin (repaglinide), 94-95, 107, 108t, 110, 125

Pravachol (pravastatin), 224t, 248t

Pravastatin (Pravachol). *See* Pravachol (pravastatin)

Prazosin (Minipress). *See* Minipress (prazosin)

Precose (acarbose), 95, 110-112, 110t, 112t, 125, 266t, 274, 346, 346t, 350

Prediabetes, 26, 87-88, 188-189, 272, 346-347, 349, 350

Preexisting conditions, insurance coverage for, 330t-331t

Pregabalin (Lyrica). *See* Lyrica (pregabalin)

Pregnancy

- diabetes during. *See* Gestational diabetes
- glucose monitoring during, 34-35
- issues to discuss with doctor, 58t
- medications to avoid during, 103, 220, 246

Premeal insulin, 124f, 139-142, 143t, 145t, 146, 151

Premixed insulin, 122-123, 123t, 136, 142, 191

Presbyesophagus, 266

Prescription

- medications, information concerning, 61, 373
- refills, 57-58

Prevalence of diabetes, 21t

Prevent Diabetes (website), 369

Prevention of diabetes, 345-355

Prilosec (omeprazole), 266, 268

Prinivil (lisinopril), 219t, 246t

Prinzide, 219t

Proactive approach to diabetes, 11

Procardia XL (nifedipine GITS), 219t

Propranolol (Inderal/Inderal LA). *See* Inderal, Inderal LA (propranolol)

Propulsid (cisapride), 267

Protein kinase C (PKC) inhibitors, 255

Protein

- deficiency, 270
- foods containing, 77-79, 78f
- limiting, 84, 179
- red blood cell carrying of, 33
- in urine, checking for, 56f

Protonix (pantoprazole), 268

Proton pump inhibitors, 268

Psychological aspects of diabetes, 369

Pulmonary function test (PFT), 135

Pump-meter combos, 165

QuackWatch (website), 370

Quality of life, 31-32, 58, 86-87, 168, 264, 345

Questions for doctors, 18-19, 57, 58t, 60, 61, 62, 63

Questran (cholestyramine), 224t, 225

Quinapril (Accupril). *See* Accupril (quinapril)

Rabeprazole (Aciphex). *See* Aciphex (rabeprazole)

Radiographic tests, 110

Ramipril (Altace). *See* Altace (ramipril)

Range of motion

- limited, 262
- exercises, 96, 262

Ranibizumab (Lucentis). *See* Lucentis (ranibizumab)
Ranitidine (Zantac). *See* Zantac (ranitidine)
Reading vision, proliferative diabetic retinopathy impact on, 253f
Record keeping, 40-41, 40f, 55, 62, 303-304. *See also* Diabetes: history sheet; Glucose: logbook
Red blood cells, 33, 34f
Red meat, 247
Reflexes, checking, 231
Reflex sympathetic dystrophy (RSD), 262
Reglan (metoclopramide), 267
Regular insulin, 59t, 130, 131t, 132, 132f, 133t, 136, 139, 141, 144f, 145t, 146, 146t, 149, 162, 305, 309
Reminders and alerts, medical, 160, 163-164, 166
Renal
 artery stenosis, 218, 245-246
 disease, 237, 242-243
Repaglinide (Prandin). *See* Prandin (repaglinide)
Resistance training, 90-92, 98
Restless sleep, 293t, 295
Retina, 252, 254
Retinal detachment, 253
Retinoids, 286-287
Retinol basement membranes, glycosylation of, 251
Retinopathy. *See* Eye: disease (diabetic retinopathy)
Rezulin (troglitazone), 111, 113, 346t, 348t, 349, 354
Rifaximin (Xifaxan). *See* Xifaxan (rifaximin)
Rimonabant (Acomplia). *See* Acomplia (rimonabant)
Risk factors for diabetes
 gestational, 26
 type 2, 28t, 347, 348t
Roche Diagnostics, 374, 377t
Rosiglitazone
 Avandia. *See* Avandia (rosiglitazone)
 glimepiride, in combination with. *See* Avandaryl (rosiglitazone/glimepiride)
 metformin, in combination with. *See* Avandamet (rosiglitazone/metformin)
Rosuvastatin (Crestor). *See* Crestor (rosuvastatin)
RSD (reflex sympathetic dystrophy), 262

Safe Driving Agreement, 331-332, 332t
Salad dressings, 75-76, 80-81
Salt, reducing, 82
Sandostatin (octreotide), 271
Sanofi-aventis US, 371, 375
Sarna, 290
Satiety and appetite, 116f, 117, 136, 138
Saturated fats, 68, 77, 79-80, 80t, 81, 83-84
Schering-Plough, 371
School settings, diabetes in, 335-336, 336t, 369
Scleredema diabeticorum, 283t
Screening tests
 for complications of diabetes, 19
 for gestational diabetes, 26
 for type 2 diabetes, 23
Secretagogues (nonsulfonylurea insulin), 104, 107, 346, 350
Secretion/absorption (food digestion), abnormalities in, 265, 271-272
Sedentary lifestyle, 50
Seizures, risk for, 96, 201, 206
Self-
 advocacy for diabetes patients, 17, 18, 19, 35, 42, 103, 325-326, 329, 338, 358, 359, 368
 care, 39, 42, 48, 367-368
 defeating thinking, 48
 employment, 315-319
 help for diabetes patients, 17
 management plan, 53
Semmes Weinstein monofilaments, 231, 232f
Sensor irregularity, 174
Serum creatinine test, 56f
Sex as exercise, 204

Sexual dysfunction, 58t, 293t, 295

SFUs. *See* Sulfonylureas (SFUs)

Shin spots. *See* Dermopathy

Shoes, selecting, 235

Short-acting insulins, 98-99, 100, 131t, 181, 309

Shoulders, diabetic conditions affecting, 262

Sick-day rules, 58t, 63-64, 234-235

Silent ischemia, 212-213

Simvastatin

- ezetimibe, in combination with. *See* Vytorin (ezetimibe/simvastatin)
- Zocor. *See* Zocor (simvastatin)

Sitagliptin

- Januvia, 114, 115t, 124-125
- metformin, in combination with. *See* Janumet (sitagliptin/metformin)

Skin

- cancer, 287
- conditions, 283, 283t, 285-290
- function of, 283

Sleep

- apnea, 291-300, 292f, 293t
 - facial structure and, 293, 294f, 296
 - as risk factor of
 - heart arrhythmias, 293
 - high blood pressure, 292-293, 295-296, 300
 - motor vehicle crashes, 300
 - stroke, 293, 300
- disorders, 48, 299
- fatigue, as caused by, 294, 296, 300
- history, 295, 300
- and overweight condition, 291
- physiological effects of, 292
- studies, 296, 298

Sleepiness, daytime, 293t, 294-296, 300

Small intestine disorders, 266t, 268-271

Smart insulin pumps, 153, 155, 156t, 160-165, 302, 357

Smart phones, 303

Smith, Chris (The Diabetic Chef), 360

Smiths Medical MD, Inc., 166f, 376

Smoking

- avoiding, 278-279, 279t
- as circulatory problem factor, 234, 236
- as heart disease risk factor, 214-215, 227

Snacks and snacking, 46, 202-204, 343t

Snoring, 291, 292f, 293t, 293-296

Social support, 49, 53-54

Sodas, 71, 93, 106, 342

Sodium, 84, 95-96

- bicarbonate/omeprazole (Zegerid). *See* Zegerid (omeprazole/sodium bicarbonate)

Solid substances, glucose control through, 205

Somogyi phenomenon, 184-185, 196-197

Sorbitol pathways, abnormal, 251

Split-mixed/premixed insulin regimen, 147, 149-150, 151t

Sporanox (itraconazole), 286

Sports drinks, 93

Squamous cell carcinoma, 287

Stable diabetes, 22

Standard (“modal”) day, 304, 306, 307f

Starlix (nateglinide), 95, 107, 108t, 110, 125, 346, 350

State

- disability laws, 334
- health insurance plans, 331t

Statins, 224, 224t, 225, 227, 248, 248t

Stem cell research, 22

Steroid injections, 260-262, 264, 287

Stiff-hand syndrome, 259-260, 260f

Stomach. *See also* Gastroparesis
 cancer of, 60f
 cramps, 311
 disorders, 266t
 ulcers, 266t, 268

STOP-NIDDM (Study to Prevent Non-Insulin-Dependent Diabetes Mellitus), 346t, 349-350

Stress, 50, 63
 hormones, 160, 293
 management, 274

Stretching exercises, 90, 92-93

Stroke
 causes of, 27
 diabetes as risk factor for, 214, 340, 341
 exercise following, 98
 expenditures on, 345
 fatal, 227
 high blood pressure as contributing factor, 244-245
 as macrovascular disease, 211
 reducing risk of, 226, 228, 357
 risk factors for (general), 213t, 348t, 351, 358
 sleep apnea as factor in, 293, 300
 as workplace challenge, 315

Study to Prevent Non-Insulin-Dependent Diabetes Mellitus (STOP-NIDDM), 346t, 349-350

Subcutaneous insulin delivery, 42

Sugar
 allowance of, 83
 foods free of, 83
 in fruit, 82

Sular (nisoldipine), 219t

Sulfonylureas (SFUs), 94, 103-108, 105t, 106f, 112-113, 118, 121, 124f, 125-126, 208-209, 266t, 273, 346

Sweeteners, artificial, 74-75

Symlin (pramlintide), 15, 59f, 95, 126, 135-139, 137f, 138t, 139f, 147, 150-151, 161, 180, 188, 215, 328

Sympathetic nerve blocks, 262

Symptoms of diabetes
 glucose level as, 25t, 32t
 at onset, 11-12, 311-312
 of type 2 diabetes, 23, 340

Systolic blood pressure, 244, 245t

Tagamet (cimetidine), 268

Taking Control of Your Diabetes (TCOYD)
 caregiver education through, 17-18, 362-364
 conferences, 18, 152f, 322f, 328, 359-360, 360f, 364, 366f
 diabetes care improvement as goal of, 31
 founding of, 16
 legal involvement of, 328-329
 newsletter, 361-362, 363f
 patient education through, 19, 359, 364-365, 368
 programs sponsored by, 43, 362-365
 publications of, 361-362, 363f
 television series, 360-361, 361f, 365
 website, 368

Tarka, 219t

Taste sensation, decrease in, 278, 278t

TCAs (tricyclic antidepressants), 232, 269

TDD (total daily dose), 155

Teeth and gums
 brushing and flossing, 276, 279-280, 279f, 279t, 282
 caring for, 276, 279-281, 282
 cleaning, 279t, 280-281
 diseases, 32, 32t
 cleaning, 279t, 280-281

Teaser (Zelnorm). *See* Zelnorm (tegaserod)

Tegretol (carbamazepine), 269

Tekturna (aliskiren), 218, 219t, 220

Telmisartan (Micardis). *See* Micardis (telmisartan)

Temperature sense, testing, 231
 Tendonitis, 92, 96
 Tenex (guanfacine), 219t
 Tenoretic, 219t
 Tenormin (atenolol), 219t
 Terazosin (Hytrin). *See* Hytrin (terazosin)
 Tests
 access to, 19
 annual, 63
 awareness of, 65
 cheating and pitfalls of, 36-37, 39, 40-41
 determining appropriate, 52, 56f, 58t
 kits, 34, 36f
 requesting, 18-19, 58
 results, communicating, 61
 Teveten (eprosartan), 219t, 247t
 Teveten HCT, 219t
 Therapy, options for, 58t
 Thiazide diuretics, 219t, 221
 Thiazolidinediones (TZDs), 104, 111-114, 113t, 118, 124, 124f, 126, 209
 Thirst
 excessive, 11-12, 23, 32, 32t, 311, 340, 342
 exercise and fluid replacement, 96
 Throat
 blockage
 cause of, 293
 panic response to, 291, 292-293
 disorders, 266t
 Thrush, 266t, 268, 285
 Thyroidectomy, 315
 Thyroid function test (TSH), 56f, 63
 Tiazac (diltiazem), 219t
 Time, adequate with doctor, 61-62
 Timolide, 219t
 Tinea pedis (athlete's foot), 284f
 Tiredness. *See* Fatigue
 Toenail fungus, 284-285, 284f
 Tolazamide (Tolinase). *See* Tolinase (tolazamide)
 Tolbutamide (Orinase). *See* Orinase (tolbutamide)
 Tolinase (tolazamide), 105t
 Topical agents, 233, 235, 287
 Toprol-XL (metoprolol), 219t
 Total daily dose (TDD), 155
 Tracheotomy, 299-300
 Trandolapril (Mavik). *See* Mavik (trandolapril)
 Trans fats, 68, 77, 79, 81, 83-84
 Transplantation, 243, 250, 315
 Traveler's Emergency Network, Inc., 371
 Traveler Insurance Services, Inc., 371
 Travel resources, 371
 Treatment for diabetes
 1968 vs current, 313
 algorithm, 123, 124f. *See also* Insulin: algorithms or sliding scales
 early, 355
 gestational, 25
 individualized, 27
 seeking out, 18-19, 65
 type 1, 21, 21t
 type 2, 21t, 22, 23, 24, 25
 TrialNet, 353, 370
 Tricor (fenofibrate), 224t, 225
 Tricyclic antidepressants (TCAs), 232, 269
 Trigger finger, 59f, 92, 260, 261f, 263-264, 264f
 Triglide (fenofibrate), 224t, 225
 Triglycerides
 as cholesterol type, 221

Triglycerides (*continued*)

- controlling, 224t, 225, 288
- elevated, 124, 272, 358
- fasting test, 222
- goal, 222t
- improving, 112, 223
- medications to treat, 224

Troglitazone (Rezulin). *See* Rezulin (troglitazone)

TSH (thyroid function test), 56f, 63

Type 1 diabetes

- case studies, 147-148, 176-180, 187-193, 196-197, 207-208, 249-250, 305-307, 309, 353-354
- continuous glucose monitoring (CGM) for, 170
- correction factor for, 141
- cure, potential for, 22
- exercise impact on, 87-88, 90t, 94
- eye disease in, 252
- gastrointestinal disorders in, 270, 272
- vs gestational diabetes, 25
- heart disease in, 213
- hypoglycemia in, 199-200, 202-208
- insulin pumps for, 153, 164
- overview of, 19, 20-22, 20t
- prevention of, 346, 352-355
- screening for, 352-355
- treatment for, 103, 151t
- vs type 2 diabetes, 21t

Type 2 diabetes

- arthritis and, 96
- case studies, 123-126, 148-150, 180-184, 193-194, 197-198, 209-210, 354-355
- causes of, 320
- in children and teens, 339-343
- cholesterol levels, impact on, 222t
- complications of, 211-212, 212f
- conditions associated with, 351
- continuous glucose monitoring (CGM) for, 170
- correction factor for, 141
- diagnosis of, 26, 123-124, 124f
- exercise impact on, 87-88, 90t, 94
- eye disease in, 252-253
- family history of, 20, 60f, 188
- gastrointestinal disorders in, 272
- vs gestational diabetes, 25
- heart disease in, 213
- hypoglycemia in, 199-200, 208-210
- ketosis in, 95
- natural history of, 23, 24f, 120
- overview of, 19, 20t, 22-24
- patient education for, 12
- prevention of, 345-352, 354-355
- risk factors for, 28t, 347, 348t
- screening for, 355
- sick-day rules for, 64
- treatment for, 124f, 151t
- vs type 1 diabetes, 21t
- weight loss, medication-related in, 117

TZDs (thiazolidinediones), 104, 111-114, 113t, 118, 124, 124f, 126, 209

Ulcer disease, 265, 267-268

Ulcers. *See also* Feet: injuries and ulcers

- mouth, 277
- neuropathic, 283t
- skin, 287
- stomach, 266t, 268

Unconsciousness

- avoiding, 42, 169
- in case studies, 189-190

Unconsciousness (*continued*)
 glucose control vs, 31
 helper action in event of, 205-206
 risk of, 201-202
 while driving, 64-65

Uncontrolled diabetes, workplace impact of, 316-317

Underweight condition, 69

Unemployed, health insurance for, 330t, 331t

Uniretic, 219t

Univasc (moexipril), 219t, 246t

Universal Travel Protection Insurance, 371

University of California, Davis, 15

University of California San Diego School of Medicine, 16

Unstable diabetes, 20

UPPP (uvulopalatopharyngoplasty), 299, 300f

Urea, 284, 286, 290

Urinary tract infections, 32, 32t

Urination, excessive, 11-14, 23, 32, 32t, 340, 342

Urine
 protein in. *See* Microalbuminuria
 testing, 13, 36, 56f
 test kits, 36f

US Office for Civil Rights, 370

Uvulopalatopharyngoplasty (UPPP), 299, 300f

Vacation
 food and drink consumption during, 12
 glucose monitoring on, 39

Vaccine against autoantibodies, 24

Vaginal infections, 32t, 268

Vague or unrealistic goals, 48-49

Valsartan (Diovan). *See* Diovan (valsartan)

Vascular
 disease, 229, 233-234, 236
 endothelial growth factor (VEGF, 253, 255-257
 permeability (leakage), 256
 reconstructive surgery, 229

Vaseline, 290

Vaseretic, 219t

Vasotec (enalapril), 219t, 246t

Vegetables
 benefits of, 45
 carbohydrates in, 73
 fiber, soluble in, 82
 importance of, 84
 nonstarchy, 83-84
 starchy, 71t, 72t
 vitamins in, 76

Vegetable vs animal protein, 247

VEGF (vascular endothelial growth factor), 253, 255-257
 inhibitors, 254, 255-256, 256f, 257

Verapamil
 Calan SR. *See* Calan SR (verapamil)
 Covera-HS. *See* Covera-HS (verapamil)
 Isoptin SR. *See* Isoptin SR (verapamil)
 Verelan. *See* Verelan (verapamil)

Verelan (verapamil), 219t

Veterans Affairs Medical Center, 16

Vibration testing, 231

Vildagliptin (Galvus). *See* Galvus (vildagliptin)

Visual impairment, preventing, 251

Vitamins, 83, 224t, 249
 B₁₂ deficiency, 231
 C, 59f, 226, 227, 249
 deficiency, 270
 E, 226, 227, 249

Vitreectomy, 253-254, 256
Vitreous hemorrhage, 254
Vocational counseling, 316
Vomiting, 64, 265, 267, 273-274, 311-312
Vytorin (ezetimibe/simvastatin), 224-225, 224t

Walking as exercise, 38t, 89-91, 96-97, 101-102, 354
Wal-Mart Pharmacies, 381t
Warm-up, pre-exercise, 98
Wartime, diabetes in, 311-313
Weight
 gain, 29, 31, 105-108, 113-114, 113t, 274
 lifting, 91-92, 97, 99t
 loss, involuntary, 11-12, 88, 117-118, 124-125, 138-139, 270, 311, 313, 342
 maintaining, 88
 measuring, 58, 60
 problems (overweight). *See* Obesity; Overweight condition
 reducing, 45, 49, 81-82, 85, 215, 272, 286, 345-346, 349-351
Welchol (colesevelam), 224t
White
 blood cells, 234
 meat, 247
Willpower, 47, 47t, 49, 53
Wine, 76-77
Workplace
 diabetes in, 314-319, 332-335, 335t, 368-369
 environment, overmodification of, 317
 health maintenance in, 343, 343t
Worldwide Assistance Services, Inc., 371
Wound
 healing, poor, 11, 32, 32t, 287
 prevention, 284
Wrist splints, 261-262
Wytensin (guanabenz), 219t

XENDOS (Xenical in the Prevention of Diabetes in Obese Subjects), 346t, 350
Xenical in the Prevention of Diabetes in Obese Subjects (XENDOS), 346t, 350
Xenical (orlistat), 346, 346t, 350
Xerosis (dry skin), 283t
Xerostomia (dry mouth), 277, 277t-278t
Xifaxan (rifaximin), 269
X-rays, 110

Yeast infections, 266, 268, 283t, 285-286

Zantac (ranitidine), 266, 268
Zebeta (bisoprolol), 219t
Zegerid (omeprazole/sodium bicarbonate), 268
Zelnorm (tegaserod), 271
Zcosorb/Zeosorb-AF, 285
Zestoretic, 219t
Zestril (lisinopril), 219t, 246t
Zetia (ezetimibe), 224, 224t
Ziac, 219t
Zocor (simvastatin), 224t, 225, 248t